Patents by Inventor John S. Kovach

John S. Kovach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulations of oxabicycloheptanes and oxabicycloheptenes
    Patent number: 11931354
    Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: March 19, 2024
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Mickey L. Wells
  • METHODS FOR TREATING SOFT TISSUE SARCOMA
    Publication number: 20240041864
    Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
    Type: Application
    Filed: June 16, 2023
    Publication date: February 8, 2024
    Inventors: John S. KOVACH, Mickey L. WELLS
  • Oxabicycloheptane prodrugs
    Patent number: 11866444
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: January 9, 2024
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert A. Volkmann, Anthony Marfat
  • COMPOSITIONS AND METHODS FOR TREATING CANCER OR PREVENTING, INHIBITING OR REDUCING RISK OF METASTASIS OF A CANCER
    Publication number: 20230310418
    Abstract: This invention provides compositions of (a) LB-100 or an LB-100 ester, or a pharmaceutically acceptable salt thereof, and (b) a WEE1 kinase inhibitor, checkpoint kinase 1 (“CHK1”) inhibitor, B-cell lymphoma-extra large (“BCL-xL”) inhibitor, BCL-xL proteolysis-targeting chimera (“BCL-xL PROTAC”), pan-BCL inhibitor or ataxia telangiectasia and Rad3-related (“ATR”) inhibitor. This invention further provides methods for treating cancer or for preventing, inhibiting, or reducing risk of metastasis of a cancer, such as colorectal cancer, cholangiocarcinoma, pancreatic cancer or ovarian cancer, using (a) LB-100 or an LB-100 ester, or a pharmaceutically acceptable salt thereof, and (b) a WEE1 kinase inhibitor, CHK1 inhibitor, BCL-xL inhibitor, BCL-xL PROTAC, pan-BCL inhibitor or ATR inhibitor.
    Type: Application
    Filed: January 3, 2023
    Publication date: October 5, 2023
    Inventors: John S. KOVACH, Rene BERNARDS, Matheus Henrique DIAS
  • OXABICYCLOHEPTANES FOR TREATMENT OF SMALL CELL LUNG CANCER
    Publication number: 20230065158
    Abstract: The present invention provides a method of treating a subject suffering from SCLC comprising administering to the subject an effective amount of a PP2A inhibitor and optionally one or more anti-cancer agents.
    Type: Application
    Filed: August 23, 2022
    Publication date: March 2, 2023
    Inventors: John S. KOVACH, Ravi SALGIA
  • CLINICAL REGIMEN FOR TREATING MYELODYSPLASTIC SYNDROME WITH PHOSPHATASE INHIBITOR
    Publication number: 20220323433
    Abstract: This invention provides a method of treating myelodysplastic syndrome in a human subject afflicted therewith comprising administering to the subject an amount from 0.1 mg/m2 to 5 mg/m2 of a compound having the structure or a salt, zwitterion, or ester thereof.
    Type: Application
    Filed: March 4, 2022
    Publication date: October 13, 2022
    Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., Lixte Biotechnology, Inc.
    Inventors: Alan F. LIST, David A. SALLMAN, John S. KOVACH
  • OXABICYCLOHEPTANE PRODRUGS
    Publication number: 20220235066
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: January 27, 2022
    Publication date: July 28, 2022
    Inventors: John S. KOVACH, Robert VOLKMANN, Anthony MARFAT
  • CLINICAL REGIMEN FOR TREATING MYELODYSPLASTIC SYNDROME WITH PHOSPHATASE INHIBITOR
    Publication number: 20220184066
    Abstract: This invention provides a method of treating myelodysplastic syndrome in a human subject afflicted therewith comprising administering to the subject an amount from 0.1 mg/m2 to 5 mg/m2 of a compound having the structure or a salt, zwitterion, or ester thereof.
    Type: Application
    Filed: March 4, 2022
    Publication date: June 16, 2022
    Inventors: ALAN F. LIST, David A. Sallman, John S. Kovach
  • Oxabicycloheptane prodrugs
    Patent number: 11236102
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: February 1, 2022
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • OXABICYCLOHEPTANES FOR ENHANCING CAR T CELL FUNCTION
    Publication number: 20210379106
    Abstract: The present invention provides a method of enhancing the function of CAR T cells comprising administering to the CAR T cells a PP2A inhibitor and optionally one or more anti-cancer therapies.
    Type: Application
    Filed: June 13, 2019
    Publication date: December 9, 2021
    Inventors: John S. KOVACH, Stephen J. FORMAN, Xiuli WANG
  • OXABICYCLOHEPTANES FOR TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIA
    Publication number: 20210275521
    Abstract: The present invention relates to compounds and methods useful for treating secondary acute myeloid leukemia (sAML).
    Type: Application
    Filed: December 5, 2018
    Publication date: September 9, 2021
    Inventor: John S. KOVACH
  • OXABICYCLOHEPTANE PRODRUGS
    Publication number: 20200325151
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: February 5, 2020
    Publication date: October 15, 2020
    Inventors: John S. KOVACH, Robert VOLKMANN, Anthony MARFAT
  • FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES
    Publication number: 20200179375
    Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
    Type: Application
    Filed: December 6, 2019
    Publication date: June 11, 2020
    Inventors: John S. Kovach, Mickey L. Wells
  • Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
    Patent number: 10668062
    Abstract: A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure (I).
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: June 2, 2020
    Assignee: Lixte Biotechnology, Inc.
    Inventor: John S. Kovach
  • Oxabicycloheptane prodrugs
    Patent number: 10618908
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: April 14, 2020
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE
    Publication number: 20200069680
    Abstract: The present invention provides a method of treating a subject afflicted with cancer comprising administering to the subject an effective amount of a PP2A inhibitor.
    Type: Application
    Filed: December 8, 2017
    Publication date: March 5, 2020
    Inventors: John S. Kovach, Zhengping Zhuang, Sze Chun Winson Ho, Herui Wang, Rongze Lu
  • Formulations of oxabicycloheptanes and oxabicycloheptenes
    Patent number: 10532050
    Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: January 14, 2020
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Mickey L. Wells
  • OXABICYCLOHEPTANE PRODRUGS
    Publication number: 20190359627
    Abstract: The present invention provides a compound having the structure:
    Type: Application
    Filed: June 12, 2019
    Publication date: November 28, 2019
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
    Patent number: 10434100
    Abstract: Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: October 8, 2019
    Assignee: Lixte Biotechnology, Inc.
    Inventors: Alan F. List, David A. Sallman, John S. Kovach
  • Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
    Patent number: 10413541
    Abstract: A method of treating a depressive or stress disorder in a subject afflicted therewith comprising administering to the subject an effective amount of a compound having the structure:
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: September 17, 2019
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Salvatore Lecca, Manuel Mameli